REFERENCES
1. Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
2. Li YY, Yu Y, Jing HB, et al. Global epidemiology of diabetes and prediabetes in lean or non-obese patients with NAFLD: a systematic review and meta-analysis. Ann Med. 2026;58:2602995.
3. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122:624-38.
4. Gebretsadik GG, Yang B, Glenn AJ, et al. Dietary manganese, type 2 diabetes, and cardiovascular disease: a UK Biobank cohort study and meta-analysis of over 270,000 individuals. J Nutr Health Aging. 2026;30:100754.
5. Wang M, Zhang SY, Zhai XR, et al. Long-term clinical outcomes in elderly patients with chronic total occlusion and type 2 diabetes: the impact of coronary collateralization following successful recanalization. Cardiology Plus. 2024;9:80-90.
6. Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17:585-607.
7. Zhuang Z, Zhu Y, Tao J, et al. UCF101 Rescues against Diabetes-Evoked Cardiac Remodeling and Contractile Anomalies through AMP-activated protein kinase-mediated induction of mitophagy. Pharmacology. 2025;110:127-40.
8. Zhang Y, Zou R, Abudureyimu M, et al. Mitochondrial aldehyde dehydrogenase rescues against diabetic cardiomyopathy through GSK3β-mediated preservation of mitochondrial integrity and Parkin-mediated mitophagy. J Mol Cell Biol. 2024;15:mjad056.
9. Jiang MY, Man WR, Zhang XB, et al. Adipsin inhibits Irak2 mitochondrial translocation and improves fatty acid β-oxidation to alleviate diabetic cardiomyopathy. Mil Med Res. 2023;10:63.
10. Dandamudi S, Slusser J, Mahoney DW, Redfield MM, Rodeheffer RJ, Chen HH. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail. 2014;20:304-9.
11. Segar MW, Khan MS, Patel KV, et al. Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults. J Am Coll Cardiol. 2021;78:1587-98.
12. Schalkwijk CG, Stehouwer CDA. Methylglyoxal, a highly reactive dicarbonyl compound, in diabetes, its vascular complications, and other age-related diseases. Physiol Rev. 2020;100:407-61.
13. Berdowska I, Matusiewicz M, Fecka I. Methylglyoxal in cardiometabolic disorders: routes leading to pathology counterbalanced by treatment strategies. Molecules. 2023;28:7742.
14. Lai SWT, Lopez Gonzalez EJ, Zoukari T, Ki P, Shuck SC. Methylglyoxal and its adducts: induction, repair, and association with disease. Chem Res Toxicol. 2022;35:1720-46.
15. Mota KO, de Vasconcelos CML, Kirshenbaum LA, Dhalla NS. The role of advanced glycation end-products in the pathophysiology and pharmacotherapy of cardiovascular disease. Int J Mol Sci. 2025;26:7311.
16. Vianello E, Beltrami AP, Aleksova A, et al. The advanced glycation end-products (AGE)-receptor for age system (RAGE): an inflammatory pathway linking obesity and cardiovascular diseases. Int J Mol Sci. 2025;26:3707.
17. Wang B, Jiang T, Qi Y, et al. AGE-RAGE axis and cardiovascular diseases: pathophysiologic mechanisms and prospects for clinical applications. Cardiovasc Drugs Ther. 2025;39:1489-506.
18. Zhang L, Huang D, Shen D, et al. Inhibition of protein kinase C βII isoform ameliorates methylglyoxal advanced glycation endproduct-induced cardiomyocyte contractile dysfunction. Life Sci. 2014;94:83-91.
19. Yang L, Yang P, Lip GYH, Ren J. Copper homeostasis and cuproptosis in cardiovascular disease therapeutics. Trends Pharmacol Sci. 2023;44:573-85.
20. Liu Y, Shen M, Zhu S, et al. Metallothionein rescues doxorubicin cardiomyopathy via mitigation of cuproptosis. Life Sci. 2025;363:123379.
21. Li P, Li Y, Meng Q, Wang J, Wang K, Yang S. Copper dyshomeostasis and cardiovascular disease: Molecular mechanisms and new strategies for targeted intervention with cuproptosis (Review). Int J Mol Med. 2026;57:19.
22. Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254-61.
23. Saha PP, Kumar SKP, Srivastava S, Sinha D, Pareek G, D’silva P. The presence of multiple cellular defects associated with a novel G50E iron-sulfur cluster scaffold protein (ISCU) mutation leads to development of mitochondrial myopathy. J Biol Chem. 2014;289:10359-77.
24. Wang Z, Wu C, Li R, et al. Cuproptosis and cardiovascular diseases: mechanisms, pathophysiology, and therapeutic strategies - a narrative review. Rev Cardiovasc Med. 2025;26:38833.
25. Wold LE, Ceylan-Isik AF, Ren J. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin. 2005;26:908-17.
26. Liu C, Zhang H, Guan R, et al. Inhibition of the HMGB1-RAGE axis attenuates microglial inflammation and ameliorates hypoxia-induced cognitive impairment. Int J Mol Sci. 2025;26:8782.
27. Chen L, Yin Z, Qin X, et al. CD74 ablation rescues type 2 diabetes mellitus-induced cardiac remodeling and contractile dysfunction through pyroptosis-evoked regulation of ferroptosis. Pharmacol Res. 2022;176:106086.
28. Shen C, Ma Y, Zeng Z, et al. RAGE-specific inhibitor FPS-ZM1 attenuates AGEs-induced neuroinflammation and oxidative stress in rat primary microglia. Neurochem Res. 2017;42:2902-11.
29. Shen L, Zhang T, Yang Y, Lu D, Xu A, Li K. FPS-ZM1 alleviates neuroinflammation in focal cerebral ischemia rats via blocking ligand/RAGE/DIAPH1 pathway. ACS Chem Neurosci. 2021;12:63-78.
30. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20:307-15.
31. Ashburner M, Ball CA, Blake JA, et al. Gene Ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25-9.
32. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 2006;34:D354-7.
33. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-50.
34. Peng H, Fu S, Wang S, et al. Ablation of FUNDC1-dependent mitophagy renders myocardium resistant to paraquat-induced ferroptosis and contractile dysfunction. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166448.
35. Chen Y, Zhao J, Ye H, et al. Beneficial impact of cardiac heavy metal scavenger metallothionein in sepsis-provoked cardiac anomalies dependent upon regulation of endoplasmic reticulum stress and ferroptosis but not autophagy. Life Sci. 2024;336:122291.
36. Ren J, Dominguez LJ, Sowers JR, Davidoff AJ. Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes. 1999;48:2059-65.
37. Quan MY, Song XJ, Liu HJ, et al. Amlexanox attenuates experimental autoimmune encephalomyelitis by inhibiting dendritic cell maturation and reprogramming effector and regulatory T cell responses. J Neuroinflammation. 2019;16:52.
38. Rani SG, Mohan SK, Yu C. Molecular level interactions of S100A13 with amlexanox: inhibitor for formation of the multiprotein complex in the nonclassical pathway of acidic fibroblast growth factor. Biochemistry. 2010;49:2585-92.
39. Ren J, Sun M, Zhou H, et al. FUNDC1 interacts with FBXL2 to govern mitochondrial integrity and cardiac function through an IP3R3-dependent manner in obesity. Sci Adv. 2020;6:eabc8561.
40. Blackburn NJR, Vulesevic B, Mcneill B, et al. Methylglyoxal-derived advanced glycation end products contribute to negative cardiac remodeling and dysfunction post-myocardial infarction. Basic Res Cardiol. 2017;112:57.
41. Li F, Hu H, Wu L, et al. Ablation of mitophagy receptor FUNDC1 accentuates septic cardiomyopathy through ACSL4-dependent regulation of ferroptosis and mitochondrial integrity. Free Radic Biol Med. 2024;225:75-86.
42. Chen N, Guo L, Wang L, Dai S, Zhu X, Wang E. Sleep fragmentation exacerbates myocardial ischemia-reperfusion injury by promoting copper overload in cardiomyocytes. Nat Commun. 2024;15:3834.
43. Huo S, Wang Q, Shi W, et al. ATF3/SPI1/SLC31A1 signaling promotes cuproptosis induced by advanced glycosylation end products in diabetic myocardial injury. Int J Mol Sci. 2023;24:1667.
44. Abramson J, Adler J, Dunger J, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630:493-500.
45. Sivaraja V, Kumar TK, Rajalingam D, Graziani I, Prudovsky I, Yu C. Copper binding affinity of S100A13, a Key Component of the FGF-1 nonclassical copper-dependent release complex. Biophys J. 2006;91:1832-43.
